Stephanie Davis
Stock Analyst at Barclays
(0.83)
# 3,864
Out of 4,918 analysts
95
Total ratings
35.29%
Success rate
-109.73%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $170.85 | +8.28% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $35.59 | +26.44% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $12.53 | -60.10% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $57.33 | +30.82% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $3.79 | +84.70% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.53 | +32.45% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $9.98 | +90.38% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $288.35 | +0.57% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $21.27 | +12.83% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $156.00 | -14.74% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $29.76 | +94.89% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.31 | +29.87% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $261.50 | -4.78% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $26.34 | +10.10% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $6.94 | +389.91% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $22.49 | +51.18% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $281.35 | -17.19% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $3.52 | +382.95% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $91.06 | -16.54% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $170.85
Upside: +8.28%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $35.59
Upside: +26.44%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $12.53
Upside: -60.10%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $57.33
Upside: +30.82%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $3.79
Upside: +84.70%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.53
Upside: +32.45%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $9.98
Upside: +90.38%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $288.35
Upside: +0.57%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $21.27
Upside: +12.83%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $156.00
Upside: -14.74%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $29.76
Upside: +94.89%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.31
Upside: +29.87%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $261.50
Upside: -4.78%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $26.34
Upside: +10.10%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $6.94
Upside: +389.91%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $22.49
Upside: +51.18%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $281.35
Upside: -17.19%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $3.52
Upside: +382.95%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $91.06
Upside: -16.54%